Stockreport

Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults

Aeterna Zentaris Inc.  (AEZS) 
Last aeterna zentaris inc. earnings: 11/7 06:28 pm Check Earnings Report
US:NASDAQ Investor Relations: zentaris.com
PDF CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) today announced that it has resubmitted a new drug app [Read more]